Allarity Secures Key Patent for Stenoparib Companion Diagnostic
Event summary
- Allarity Therapeutics received a Notice of Allowance from the USPTO for a patent covering its Stenoparib DRP® companion diagnostic.
- The patent, expected to be formally granted within three months, provides exclusivity for stenoparib use with the DRP® test until at least 2039.
- The patent covers methods for predicting clinical benefit and selecting patients based on gene expression profiles.
- Allarity previously secured patents in Europe and Australia for the Stenoparib DRP® and holds 18 granted patents for other drug-specific DRPs.
The big picture
The patent strengthens Allarity's position in the increasingly competitive personalized oncology space, where companion diagnostics are becoming essential for drug efficacy and regulatory approval. Securing broad patent protection for the DRP® platform is a strategic move to maximize the value of stenoparib, particularly given the growing focus on targeted therapies and the need to improve clinical trial success rates. This patent provides a significant barrier to entry for competitors seeking to develop similar PARP/tankyrase inhibitors with companion diagnostics.
What we're watching
- Patent Defense
- The company's ability to successfully defend this patent against potential challenges from competitors will be crucial for maintaining its exclusivity and commercial advantage.
- Clinical Adoption
- The pace at which oncologists adopt the Stenoparib DRP® test in clinical practice will determine the real-world impact on stenoparib's market penetration and revenue generation.
- Regulatory Approval
- How the USPTO's decision and the patent's scope influence the FDA's review and potential approval pathway for stenoparib will be a key indicator of its long-term commercial viability.
Related topics